Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Xtant Medical Holdings (XTNT) EBITDA (2016 - 2025)

Xtant Medical Holdings has reported EBITDA over the past 16 years, most recently at $17.8 million for Q4 2025.

  • Quarterly EBITDA rose 161.97% to $17.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.0 million through Dec 2025, up 860.6% year-over-year, with the annual reading at $5.3 million for FY2025, 131.49% up from the prior year.
  • EBITDA was $17.8 million for Q4 2025 at Xtant Medical Holdings, up from $2.5 million in the prior quarter.
  • Over five years, EBITDA peaked at $17.8 million in Q4 2025 and troughed at -$3.8 million in Q4 2023.
  • The 5-year median for EBITDA is -$1.5 million (2021), against an average of $90050.0.
  • Year-over-year, EBITDA tumbled 36520.0% in 2022 and then soared 278.06% in 2024.
  • A 5-year view of EBITDA shows it stood at -$1.9 million in 2021, then increased by 9.79% to -$1.7 million in 2022, then plummeted by 120.77% to -$3.8 million in 2023, then soared by 278.06% to $6.8 million in 2024, then skyrocketed by 161.97% to $17.8 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's EBITDA are $17.8 million (Q4 2025), $2.5 million (Q3 2025), and $4.6 million (Q2 2025).